Letter to the Editor: Akkermansia muciniphila serves as an immunomodulator for type 1 diabetes mellitus: Promises and pitfalls

Abstract

We read with great interest the study by Huang et al published in the recent issue of the World Journal of Diabetes, which presented the potential of Akkermansia muciniphila (A. muciniphila) as an immunomodulator in a murine model of type 1 diabetes mellitus (T1DM). However, several concerns about translating these results into clinical applications warrant attention. Firstly, despite the observed improvements in immune regulation, particularly the enhancement of Tregs and the reduction of pro-inflammatory cytokines, A. muciniphila did not reverse the hyperglycemia or restore insulin production in the mice. This raises questions about the feasibility of using A. muciniphila as a therapeutic agent in advanced stages of T1DM, where β-cell destruction is likely irreversible. Additionally, the specific effect of A. muciniphila on immune pathways in T1DM remains unclear, and the possibility of unforeseen immune responses needs further exploration. While another important consideration is the potential long-term effects of altering gut microbiota composition, as the reduction in Actinobacteria could have broader implications for gut health, which were not fully addressed in the study. Therefore, while the findings are promising, further studies are essential to evaluate the long-term safety and efficacy of A. muciniphila in clinical settings, particularly for individuals with established T1DM.

Key Words: Type 1 diabetes mellitus; Akkermansia muciniphila; Immunomodulator; Gut microbiota; Clinical application

Core Tip: This article offers a critical evaluation of the therapeutic potential of Akkermansia muciniphila in the context of type 1 diabetes mellitus. While the study has yielded promising results in terms of immunomodulatory effects, the absence of metabolic reversal highlights significant challenges in translating these findings into clinical applications. This article emphasizes the need for caution regarding the inhibition of immune pathways, interspecies variability, and potential ecological trade-offs within the gut microbiome. Future investigations should prioritize clinical trials and combination therapies to realize its therapeutic potential in type 1 diabetes mellitus.

TO THE EDITOR

We read with great interest and appreciation the recent study by Huang et al[1] published in the World Journal of Diabetes, which provides timely evidence regarding the therapeutic potential of the next-generation probiotic Akkermansia muciniphila (A. muciniphila) in the context of type 1 diabetes mellitus (T1DM).

A. muciniphila is a Gram-negative, anaerobic, mucin-degrading commensal that preferentially inhabits the intestinal mucus layer and is considered a “keystone” mucus-associated species in many hosts. A. muciniphila it has garnered attention for its multifaceted benefits, including enhancing gut barrier integrity, improving metabolic parameters, stimulating glucagon-like peptide-1secretion, and exerting anti-inflammatory effects.

The authors meticulously demonstrated that oral administration of A. muciniphila could mitigate immune dysregulation in streptozotocin (STZ)-induced diabetic mice, in which the potential mechanism was closely related to the restoration of the balance between regulatory T cells (Tregs) and Th1 cells, the suppression of pro-inflammatory cytokines, as well as the enhancement of intestinal barrier integrity.

These findings align with a growing body of literature suggesting that the gut microbiome acts as an extra genomic regulator of autoimmune progression[2]. Given that T1DM is characterized by the autoimmune destruction of pancreatic β-cells, often preceded by gut dysbiosis and increased intestinal permeability, the strategy of targeting the gut-immune axis demonstrates a paradigm shift in T1DM management[3]. This study serves as a crucial concept proof, reinforcing the notion that A. muciniphila is not merely a mucin-degrading specialist but also a potent modulator of systemic immunity.

However, as we applaud these preclinical advances, it is incumbent upon the scientific community to critically evaluate the translational gap between murine efficacy and human clinical reality. The transition from a controlled laboratory setting to the complex heterogeneity of human T1DM is fraught with challenges. Upon close examination of the data presented by Huang et al[1], alongside current literature, several critical concerns emerge. These concerns - ranging from the disconnect between immunomodulation and metabolic recovery, to the intricacies of signaling pathways, and finally, the long-term impact on the gut microbiome - warrant a comprehensive discussion. Hence, this letter aims to elucidate these pitfalls to ensure that the promises of A. muciniphila are pursued with scientific rigor and caution.

DISCONNECT BETWEEN IMMUNE REGULATION AND METABOLIC REVERSAL

The most striking observation in the study by Huang et al[1], which the authors candidly acknowledged, is the dissociation between immune biomarkers and metabolic outcomes. While A. muciniphila treatment successfully skewed the immune profile toward an anti-inflammatory phenotype (increasing Tregs and reducing Th1 cytokines), it failed to reverse hyperglycemia or restore insulin levels in the STZ-treated mice. This outcome exposes a fundamental limitation in using immunomodulatory probiotics for established T1DM: The issue of irreversibility in β-cell mass.

In the STZ-induced model, β-cell destruction is rapid and driven by alkylating toxicity, which differs kinetically from the slow, waxing-and-waning autoimmune assault observed in humans[4]. However, the clinical implication remains consistent: Once a critical threshold of β-cell mass is lost (typically estimated at 80%-90% at the time of clinical diagnosis in humans), immune regulation alone is insufficient to restore normoglycemia. The inability of A. muciniphila to stimulate insulin production means that, although the bacterium may arrest further autoimmune damage, it cannot provide regenerative effects for the islets of Langerhans. It should be noted that this distinction is crucial. In the context of type 2 diabetes mellitus, A. muciniphila has been shown to improve glucose handling primarily by enhancing insulin sensitivity as well as reducing metabolic endotoxemia[5]. However, in T1DM, where the core pathology is absolute insulin deficiency, improving sensitivity is futile if the source of insulin is eradicated.

Hence, the clinical utility of A. muciniphila may be strictly time-dependent. Its potential efficacy is likely confined to the pre-symptomatic stages (stage 1 or stage 2 T1DM, defined by the presence of autoantibodies without dysglycemia) or the honeymoon phase shortly after diagnosis, where residual β-cell function is still preserved[6]. The use of A. muciniphila in advanced T1DM, in the absence of concurrent regenerative therapies or exogenous insulin, is unlikely to yield significant metabolic benefits. Furthermore, the short duration of this research raises questions about the temporal dynamics of efficacy. Would long-term colonization of the microbiome lead to sustained metabolic improvements, or would the host develop tolerance to the bacterial signals over time? Future research should pivot from treating established diabetes to preserving residual beta-cell function to properly adding A. muciniphila as a therapeutic intervention within the broader therapeutic landscape.

COMPLEXITY OF IMMUNOMODULATION AND INTERSPECIES VARIANCE

The second major concern lies in the mechanistic pathways highlighted in the study, specifically the downregulation of nuclear factor kappaB (NF-κB) and signal transducer and activator of transcription 1 signaling. Huang et al[1] propose that the suppression of these pathways constitutes the primary mechanism underlying the observed reduction in inflammation. While such a mechanism is plausible within the context of modulating autoimmunity, the application of broad pathway inhibition to human subjects must be approached with considerable caution, given the pleiotropic nature of these signaling hubs.

The NF-κB pathway is often described as a classic “double-edged sword”. In the context of T1DM, its activation undeniably contributes to the expression of pro-inflammatory cytokines and chemokines, which subsequently recruit immune cells to the islets, leading to insulitis. However, basal NF-κB activity is also essential for cell survival, anti-apoptotic signaling, as well as the initiation of effective immune responses against pathogens[7]. Thus, the suppression of NF-κB by probiotic intervention could theoretically compromise the ability of the host to mount an adequate defense against infections, in whom the risk is particularly pertinent in diabetic patients who are already prone to infectious complications.

Moreover, the extrapolation of immune findings from STZ-induced mice to humans is complicated by inherent interspecies differences. Notably, human T1DM is a genetically complex disease strongly associated with human leukocyte antigen class II polymorphisms and involves a sophisticated interplay between autoreactive CD4+ T cells and CD8+ T cells, B cells, and dendritic cells[8]. In contrast, the STZ model predominantly hinges on chemical toxicity to provoke the release of autoantigens, subsequently initiating a secondary inflammatory cascade. The murine immune system differs significantly from the human system in terms of Toll-like receptor (TLR) expression distributions, macrophage activation phenotypes, and the composition of defensins[9]. Particularly, A. muciniphila is known to interact with TLR2 via its outer membrane protein Amuc_1100[10]. Should the expression or sensitivity of TLR2 differ between the murine and human gut epithelium under diabetic conditions, the immunomodulatory effects observed in mice may not be directly translatable to human models. Thus, reliance on specific pathway inhibition (like NF-κB/signal transducer and activator of transcription 1) observed in mice may oversimplify the complex, redundant immune networks operative in human T1DM.

Besides, it is also worth noting that the immunomodulatory capacity of A. muciniphila may extend beyond T1DM to a broader spectrum of inflammatory and autoimmune disorders, given its core mechanisms of enhancing Tregs and dampening inflammation. This wider applicability warrants exploration but does not diminish the specific translational challenges in T1DM.

ECOLOGICAL TRADE-OFFS AND THE ACTINOBACTERIA PARADOX

While associations between microbiota composition and metabolic diseases like obesity and type 2 diabetes mellitus are well-documented, establishing causality remains challenging[11]. Recent advancements in sequencing technologies have accelerated research into the role of gut microbiome in health and disease. Notably, A. muciniphila has been shown to correct metabolic disorders in obese insulin-resistant mice, and its combination with butyrate exhibits synergistic therapeutic potential in diabetes[12]. Moreover, dietary interventions like alternate day fasting can enrich A. muciniphila, thereby alleviating diabetic neuroinflammation via the gut-liver-brain axis[13]. These findings highlight the potential of A. muciniphila as a key microbial mediator, but also underline the complexity of its ecological interactions.

Furthermore, perhaps the most nuanced and overlooked aspect of the study pertains to the alteration of the broader gut microbiota composition. Huang et al[1] reported a reduction in the relative abundance of the phylum Actinobacteria following the administration of A. muciniphila, interpreting this shift as a favorable outcome associated with the attenuation of T1DM. However, we contend that this interpretation warrants critical re-evaluation, as it potentially overlooks a significant ecological pitfall.

The phylum Actinobacteria encompasses the genus Bifidobacterium, which is widely recognized as one of the most beneficial groups of gut commensals. Numerous studies have documented that individuals with T1DM, particularly children, exhibit a significantly lower abundance of Bifidobacterium compared to healthy controls, suggesting that the depletion of this genus constitutes a pathological feature of the disease rather than a protective mechanism[14,15].

However, it should be noted that Bifidobacteria are essential producers of acetate and lactate, and through a process referred to as cross-feeding, these metabolites serve as critical substrates for other butyrate-producing bacteria, such as Faecalibacterium prausnitzii and Eubacterium hallii[16,17]. Butyrate, in turn, is crucial for the differentiation of Tregs and the maintenance of colonic epithelial integrity[18]. Therefore, should the introduction of A. muciniphila result in the competitive suppression of Actinobacteria, it could inadvertently disrupt this cross-feeding network. Although A. muciniphila itself produces acetate and propionate, a diverse microbiome is generally more resilient and functional than one dominated by a single species. Thus, the reduction in Actinobacteria could signify an ecological imbalance or trade-off, wherein the dominance of A. muciniphila occurs at the expense of other beneficial microbial clades.

This raises a critical safety concern: Does long-term supplementation with high concentrations of A. muciniphila lead to a reduction in microbial diversity? Especially in the context of T1DM, where diversity is already compromised, further reduction may have unforeseen negative consequences for long-term gut health, even if it is purported probiotic driven. Thus, we should shift our focus from the analysis of individual bacterial alterations to a more holistic consideration of the functional ecology of the microbiome. The ultimate objective should be the restoration of a balanced ecosystem, rather than merely promoting the abundance of a single species while suppressing a phylum that contains other beneficial microbial members.

CONCLUSION

In conclusion, the study by Huang et al[1] represents a significant step forward in elucidating the immunomodulatory capabilities of A. muciniphila in T1DM. The findings regarding Treg enhancement and barrier repair are indisputably promising. However, the journey from a murine STZ model to a viable clinical therapy is riddled with complexities that cannot be ignored (Figure 1).

Figure 1 The schematic diagram. A. muciniphila: Akkermansia muciniphila; ZO-1: Zonula occludens-1; TNF: Tumor necrosis factor; IFN: Interferon; Foxp3: Forkhead box P3; T-bet: T-box expressed in T cells; NF-κB: Nuclear factor kappaB.

The absence of metabolic reversal underscores the necessity of positioning this intervention as a preventive or early-stage adjunct, rather than a curative treatment for established disease. The widespread suppression of immune pathways, such as NF-κB, calls for comprehensive safety profiling to exclude the potential for immunosuppressive side effects in human subjects. Perhaps most critically, the observed reduction in Actinobacteria serves as a cautionary note against adopting a reductionist view of the microbiome. It is essential that, in addressing one form of dysbiosis, we do not inadvertently create another by depleting vital symbiotic partners, such as Bifidobacteria.

We strongly advocate that future investigations prioritize: (1) Longitudinal studies to assess the long-term safety and ecological impact of A. muciniphila administration on the human gut microbiome; (2) Combinatorial approaches that integrate A. muciniphila with insulin therapy or other probiotics to preserve microbial community diversity; (3) Trials involving humanized murine models or clinical pilot studies in recent-onset T1DM patients to better gauge the translational efficacy; and (4) Exploration of natural sources (e.g., dietary fibers like pectin and fructo-oligosaccharides) or synbiotic formulations that can promote endogenous A. muciniphila growth, thus offering a more sustainable and ecologically balanced intervention. Only by addressing these critical issues can the full therapeutic potential of A. muciniphila be realized in the battle against T1DM.